GPX3 and B-cell chronic lymphocytic leukemia: In contrast, in the CLL cybrids, treatment with ibrutinib alone caused a significant increase in the relative fold change of SOD2 (1.7-fold change, p < 0.01), GPX3 (1.8-fold change, p < 0.0001), and NOX4 (0.9-fold change, p < 0.0001) expression.